THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
Identifieur interne : 003720 ( Main/Exploration ); précédent : 003719; suivant : 003721THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
Auteurs : David Scott [Royaume-Uni] ; David Scott [Royaume-Uni] ; Paul Bacon [Royaume-Uni]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 1982-08.
English descriptors
- Teeft :
- Acute phase proteins, Acute phase response, Adverse reactions, Annals, Antiinflammatory drugs, Arthritis, Aspirin, Bladder toxicity, Blood dyscrasias, Clinical benefits, Clinical practice, Clinical response, Clinics committee, Considerable debate, Conventional drugs, Crockson, Cyclophosphamide, Cytotoxic, Cytotoxic drugs, Disease activity, Dos, Drug treatment, England journal, Further studies, High levels, Individual patient, Joint damage, Late side effects, Mcconkey, Medical journal, Myasthenia gravis, Newer drugs, Nonsteroidal drugs, Nsaid, Other drugs, Other workers, Penicillamine, Prospective studies, Prostaglandin, Prostaglandin synthesis, Radiological changes, Recent years, Rheumanc diseases, Rheumatic, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid disease, Rheumatoid factor, Secondline drugs, Serum protein, Severe disease, Side effects, Significant problem, Similar effects, Steroid, Wide variety.
Abstract
Anti‐rheumatic drugs used in rheumatoid arthritis fall into two distinct groups: non‐steroidal anti‐inflammatory and second‐line drugs. Non‐steroidal anti‐inflammatory drugs give early symptomatic improvement and reduce the degree of acute inflammatory synovitis. Second‐line drugs such as gold or D penicillamine exert an anti‐inflammatory effect only after two to three months and act by suppressing disease activity: these reduce the ESR and other acute phase responses. However, the evidence that any of these drugs halt the progression of radiological changes or can be used as long‐term agents to control the disease over a period of years is weak. The current use of anti‐rheumatic drugs follows a general pattern with nonsteroidal anti‐inflammatory drugs used alone in patients with mild disease, whereas patients with severe disease also receive second‐line drugs. As yet the long‐term effect of this policy is not known. Cytotoxic drugs should be restricted to patients with severe disease who either fail to respond to conventional second‐line drugs or have active extra‐articular disease, particularly those with vasculitis.
Url:
DOI: 10.1111/j.1365-2710.1982.tb01027.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000316
- to stream Istex, to step Curation: 000316
- to stream Istex, to step Checkpoint: 002479
- to stream Main, to step Merge: 003799
- to stream Main, to step Curation: 003720
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS</title><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name></author><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name></author><author><name sortKey="Bacon, Paul" sort="Bacon, Paul" uniqKey="Bacon P" first="Paul" last="Bacon">Paul Bacon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A2819C623247D858C1AD34449388A5AAE39F5705</idno><date when="1982" year="1982">1982</date><idno type="doi">10.1111/j.1365-2710.1982.tb01027.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-2P6NCG92-6/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000316</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000316</idno><idno type="wicri:Area/Istex/Curation">000316</idno><idno type="wicri:Area/Istex/Checkpoint">002479</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002479</idno><idno type="wicri:doubleKey">0269-4727:1982:Scott D:therapeutic:progress:review</idno><idno type="wicri:Area/Main/Merge">003799</idno><idno type="wicri:Area/Main/Curation">003720</idno><idno type="wicri:Area/Main/Exploration">003720</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">THERAPEUTIC PROGRESS—REVIEW VI*TREATMENT OF RHEUMATOID ARTHRITIS</title><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Bacon, Paul" sort="Bacon, Paul" uniqKey="Bacon P" first="Paul" last="Bacon">Paul Bacon</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Departments of Rheumatology and Investigative Pathology, Queen Elizabeth Hospital, Birmingham 15</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">7</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="217">217</biblScope><biblScope unit="page" to="229">229</biblScope><biblScope unit="page-count">13</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1982-08">1982-08</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute phase proteins</term><term>Acute phase response</term><term>Adverse reactions</term><term>Annals</term><term>Antiinflammatory drugs</term><term>Arthritis</term><term>Aspirin</term><term>Bladder toxicity</term><term>Blood dyscrasias</term><term>Clinical benefits</term><term>Clinical practice</term><term>Clinical response</term><term>Clinics committee</term><term>Considerable debate</term><term>Conventional drugs</term><term>Crockson</term><term>Cyclophosphamide</term><term>Cytotoxic</term><term>Cytotoxic drugs</term><term>Disease activity</term><term>Dos</term><term>Drug treatment</term><term>England journal</term><term>Further studies</term><term>High levels</term><term>Individual patient</term><term>Joint damage</term><term>Late side effects</term><term>Mcconkey</term><term>Medical journal</term><term>Myasthenia gravis</term><term>Newer drugs</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Other drugs</term><term>Other workers</term><term>Penicillamine</term><term>Prospective studies</term><term>Prostaglandin</term><term>Prostaglandin synthesis</term><term>Radiological changes</term><term>Recent years</term><term>Rheumanc diseases</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid disease</term><term>Rheumatoid factor</term><term>Secondline drugs</term><term>Serum protein</term><term>Severe disease</term><term>Side effects</term><term>Significant problem</term><term>Similar effects</term><term>Steroid</term><term>Wide variety</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anti‐rheumatic drugs used in rheumatoid arthritis fall into two distinct groups: non‐steroidal anti‐inflammatory and second‐line drugs. Non‐steroidal anti‐inflammatory drugs give early symptomatic improvement and reduce the degree of acute inflammatory synovitis. Second‐line drugs such as gold or D penicillamine exert an anti‐inflammatory effect only after two to three months and act by suppressing disease activity: these reduce the ESR and other acute phase responses. However, the evidence that any of these drugs halt the progression of radiological changes or can be used as long‐term agents to control the disease over a period of years is weak. The current use of anti‐rheumatic drugs follows a general pattern with nonsteroidal anti‐inflammatory drugs used alone in patients with mild disease, whereas patients with severe disease also receive second‐line drugs. As yet the long‐term effect of this policy is not known. Cytotoxic drugs should be restricted to patients with severe disease who either fail to respond to conventional second‐line drugs or have active extra‐articular disease, particularly those with vasculitis.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Midlands de l'Ouest</li></region><settlement><li>Birmingham</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name></region><name sortKey="Bacon, Paul" sort="Bacon, Paul" uniqKey="Bacon P" first="Paul" last="Bacon">Paul Bacon</name><name sortKey="Scott, David" sort="Scott, David" uniqKey="Scott D" first="David" last="Scott">David Scott</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003720 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003720 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A2819C623247D858C1AD34449388A5AAE39F5705
|texte= THERAPEUTIC PROGRESS—REVIEW VITREATMENT OF RHEUMATOID ARTHRITIS
}}
| This area was generated with Dilib version V0.6.33. |  |